Skip to main content
SpringerLink
Log in

Liver Disease in Pediatric Inflammatory Bowel Disease

  • Chapter
  • First Online:
Pediatric Inflammatory Bowel Disease

Abstract

Children with inflammatory bowel diseases (IBD) are at higher risk of developing liver diseases, compared to the general population. A percentage of these children will develop chronic liver diseases such as primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and autoimmune sclerosing cholangitis (ASC, an overlap syndrome). With the use of medications to control intestinal inflammation, hepatotoxicity can also occur in this population. A smaller group of children may acquire rare liver complications, including, but not limited to neoplastic processes, hepatic abscesses, or venous thrombosis. Although the development of abnormal liver biochemistry in children with IBD can be transient, the clinician must be vigilant in their assessment of the child, taking these complications into consideration. In this chapter we will review the liver diseases reported to be associated with pediatric IBD, and we will outline a diagnostic algorithm for the assessment of abnormal liver biochemistry.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.

    Article  PubMed  CAS  Google Scholar 

  2. Yamamoto-Furusho JK, Sanchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann Hepatol. 2010;9:397–401.

    PubMed  Google Scholar 

  3. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106–14.

    Article  PubMed  Google Scholar 

  4. Nemeth A, Ejderhamn J, Glaumann H, Strandvik B. Liver damage in juvenile inflammatory bowel disease. Liver. 1990;10:239–48.

    PubMed  CAS  Google Scholar 

  5. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042–9.

    Article  PubMed  Google Scholar 

  6. Warren KW, Athanassiades S, Monge JI. Primary sclerosing cholangitis. A study of forty-two cases. Am J Surg. 1966;111:23–38.

    Article  PubMed  CAS  Google Scholar 

  7. Dotson J, Hyams J, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51:140–5.

    Article  PubMed  Google Scholar 

  8. Mieli-Vergani G, Vergani D. Unique features of primary sclerosing cholangitis in children. Curr Opin Gastroenterol. 2010;26:265–8.

    Article  PubMed  Google Scholar 

  9. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009;7:239–45.

    Article  PubMed  Google Scholar 

  10. Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18:154–61.

    Article  PubMed  Google Scholar 

  11. Loftus Jr EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.

    Article  PubMed  Google Scholar 

  12. Schwarze C, Terjung B, Lilienweiss P, et al. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. Clin Exp Immunol. 2003;133:283–9.

    Article  PubMed  CAS  Google Scholar 

  13. Kerkar N, Miloh T. Sclerosing cholangitis: pediatric perspective. Curr Gastroenterol Rep. 2010;12:195–202.

    Article  PubMed  Google Scholar 

  14. Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 2000;32:182–7.

    Article  PubMed  CAS  Google Scholar 

  15. Majoie CB, Reeders JW, Sanders JB, Huibregtse K, Jansen PL. Primary sclerosing cholangitis: a modified classification of cholangiographic findings. AJR Am J Roentgenol. 1991;157:495–7.

    PubMed  CAS  Google Scholar 

  16. Ferrara C, Valeri G, Salvolini L, Giovagnoni A. Magnetic resonance cholangiopancreatography in primary sclerosing cholangitis in children. Pediatr Radiol. 2002;32:413–7.

    Article  PubMed  Google Scholar 

  17. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1–10.

    Article  PubMed  CAS  Google Scholar 

  18. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335:909–18.

    Article  PubMed  CAS  Google Scholar 

  19. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544–53.

    Article  PubMed  CAS  Google Scholar 

  20. Rasmussen HH, Fallingborg J, Mortensen PB, et al. Primary sclerosing cholangitis in patients with ulcerative colitis. Scand J Gastroenterol. 1992;27:732–6.

    Article  PubMed  CAS  Google Scholar 

  21. Dew MJ, Thompson H, Allan RN. The spectrum of hepatic dysfunction in inflammatory bowel disease. Q J Med. 1979;48:113–35.

    PubMed  CAS  Google Scholar 

  22. Ibrahim SH, Lindor KD. Current management of primary sclerosing cholangitis in pediatric patients. Paediatr Drugs. 2011;13:87–95.

    Article  PubMed  Google Scholar 

  23. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology. 1990;12:486–91.

    Article  PubMed  CAS  Google Scholar 

  24. Lindor KD. Ursodiol for primary sclerosing cholangitis. N Engl J Med. 1997;336:691–5.

    Article  PubMed  CAS  Google Scholar 

  25. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008;47:61–7.

    Article  PubMed  CAS  Google Scholar 

  26. Gotthardt D, Stiehl A. Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis. Clin Liver Dis. 2010;14:349–58.

    Article  PubMed  Google Scholar 

  27. Gluck M, Cantone NR, Brandabur JJ, Patterson DJ, Bredfeldt JE, Kozarek RA. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032–9.

    Article  PubMed  Google Scholar 

  28. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology. 2002;35:1494–500.

    Article  PubMed  Google Scholar 

  29. Miloh T, Anand R, Yin W, et al. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl. 2011;17:925–33.

    Article  PubMed  Google Scholar 

  30. Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol. 2010;53:313–7.

    Article  PubMed  Google Scholar 

  31. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology. 1989;96:790–4.

    PubMed  CAS  Google Scholar 

  32. Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut. 1994;35:84–9.

    Article  PubMed  CAS  Google Scholar 

  33. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.

    Article  PubMed  CAS  Google Scholar 

  34. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children. Clin Liver Dis. 2002;6:623–34.

    Article  PubMed  Google Scholar 

  35. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997;25:1105–7.

    Article  PubMed  CAS  Google Scholar 

  36. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.

    Article  PubMed  CAS  Google Scholar 

  37. Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? Clin Gastroenterol Hepatol. 2004;2:935–40.

    Article  PubMed  Google Scholar 

  38. McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998;93:777–84.

    Article  PubMed  CAS  Google Scholar 

  39. Gohlke F, Lohse AW, Dienes HP, et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol. 1996;24:699–705.

    Article  PubMed  CAS  Google Scholar 

  40. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–7.

    Article  PubMed  CAS  Google Scholar 

  41. Berends MA, Snoek J, de Jong EM, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther. 2006;24:805–11.

    Article  PubMed  CAS  Google Scholar 

  42. Rampton DS. Methotrexate in Crohn’s disease. Gut. 2001;48:790–1.

    Article  PubMed  CAS  Google Scholar 

  43. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60:824–37.

    Article  PubMed  Google Scholar 

  44. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465–82.

    Article  Google Scholar 

  45. Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105:1620–6.

    Article  PubMed  CAS  Google Scholar 

  46. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150–6.

    Article  PubMed  CAS  Google Scholar 

  47. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol. 2007;102:2804–12.

    Article  PubMed  CAS  Google Scholar 

  48. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn’s disease: a French multicenter study. Inflamm Bowel Dis. 2006;12:1053–7.

    Article  PubMed  CAS  Google Scholar 

  49. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol. 2001;16:1395–401.

    Article  PubMed  CAS  Google Scholar 

  50. Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:659–66.

    Article  PubMed  CAS  Google Scholar 

  51. Viazis N, Vlachogiannakos J, Georgiadis D, et al. Azathioprine use in patients with inflammatory bowel disease. Adherence to treatment and adverse events. A single center experience. Ann Gastroenterol. 2009;22:173–7.

    Google Scholar 

  52. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007;102:2488–94.

    Article  PubMed  CAS  Google Scholar 

  53. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:331–42.

    Article  PubMed  CAS  Google Scholar 

  54. Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2005;39:21–6.

    PubMed  CAS  Google Scholar 

  55. Bouhnik Y, Lemann M, Mary J, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-­mercaptopurine. Lancet. 1996;347:215–9.

    Article  PubMed  CAS  Google Scholar 

  56. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–42.

    PubMed  CAS  Google Scholar 

  57. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641–9.

    PubMed  CAS  Google Scholar 

  58. Holtmann M, Schreiner O, Kohler H, et al. Veno-occlusive disease (VOD) in Crohn’s disease (CD) treated with azathioprine. Dig Dis Sci. 2003;48:1503–5.

    Article  PubMed  CAS  Google Scholar 

  59. Roda G, Caponi A, Belluzzi A, Roda E. Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis. Dig Liver Dis. 2009;41:914–5.

    Article  PubMed  CAS  Google Scholar 

  60. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007;56:1404–9.

    Article  PubMed  CAS  Google Scholar 

  61. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut. 1996;39:401–6.

    Article  PubMed  CAS  Google Scholar 

  62. Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis. 2008;14:750–5.

    Article  PubMed  Google Scholar 

  63. Kader H, Wenner WJ, Telega G, Mailer E, Baldassano R. Normal thiopurine methyltransferase levels do not eliminate 6- mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000;30:409–13.

    Article  PubMed  CAS  Google Scholar 

  64. IMURAN (azathioprine) Product information. 2011. Accessed at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016324s034s035lbl.pdf.

  65. Besnard M, Debray D, Durand P, Fabre M, Chardot C, Cezard JP. Fulminant hepatitis in two children treated with sulfasalazine for Crohn disease. Arch Pediatr. 1999;6:643–6.

    Article  PubMed  CAS  Google Scholar 

  66. Boyer DL, Li BU, Fyda JN, Friedman RA. Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1989;8:528–32.

    Article  PubMed  CAS  Google Scholar 

  67. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275:43–61.

    Article  PubMed  CAS  Google Scholar 

  68. Candelli M, Nista EC, Pignataro G, et al. Steatohepatitis during methylprednisolone therapy for ulcerative colitis exacerbation. J Intern Med. 2003;253:391–2.

    Article  PubMed  CAS  Google Scholar 

  69. Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. 2011;31:327–37.

    Article  PubMed  CAS  Google Scholar 

  70. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:937–43.

    Article  PubMed  CAS  Google Scholar 

  71. Schatorje E, Hoekstra H. Transient hypertransaminasemia in paediatric patients with Crohn disease undergoing initial treatment with enteral nutrition. J Pediatr Gastroenterol Nutr. 2010;51:336–40.

    PubMed  CAS  Google Scholar 

  72. Dolz C, Xiol X, Abad A, et al. Changes in liver function tests in patients with inflammatory bowel disease on enteral nutrition. JPEN: J Parenter Enteral Nutr. 1989;13:401–5.

    Article  CAS  Google Scholar 

  73. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024–30.

    Article  PubMed  Google Scholar 

  74. Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011;23:1150–6.

    Article  PubMed  CAS  Google Scholar 

  75. Jose F, Garnett E, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63–8.

    Article  PubMed  Google Scholar 

  76. Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut. 2003;52:1117–21.

    Article  PubMed  CAS  Google Scholar 

  77. Kratzer W, Haenle M-M, Mason R-A, von Tirpitz C, Kaechele V. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005;11:6170–5.

    PubMed  Google Scholar 

  78. Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201–4.

    Article  PubMed  CAS  Google Scholar 

  79. Hutchinson R, Tyrrell PN, Kumar D, Dunn JA, Li JK, Allan RN. Pathogenesis of gall stones in Crohn’s disease: an alternative explanation. Gut. 1994;35:94–7.

    Article  PubMed  CAS  Google Scholar 

  80. Brink MA, Slors JF, Keulemans YC, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn’s disease. Gastroenterology. 1999;116:1420–7.

    Article  PubMed  CAS  Google Scholar 

  81. Akerlund JE, Einarsson C. Effects of colectomy on bile composition, cholesterol saturation and cholesterol crystal formation in humans. Int J Colorectal Dis. 2000;15:248–52.

    Article  PubMed  CAS  Google Scholar 

  82. Navot-Mintzer D, Koren A, Shahbari A, Nussinson E, Sakran W. Liver abscesses as the presenting manifestation of Crohn’s disease in an adolescent. Inflamm Bowel Dis. 2006;12:666–7.

    Article  PubMed  Google Scholar 

  83. Song J, Swekla M, Colorado P, Reddy R, Hoffmann S, Fine S. Liver abscess and diarrhea as initial manifestations of ulcerative colitis: case report and review of the literature. Dig Dis Sci. 2003;48:417–21.

    Article  PubMed  Google Scholar 

  84. Greenstein AJ, Sachar DB, Lowenthal D, Goldofsky E, Aufses Jr AH. Pyogenic liver abscess in Crohn’s disease. Q J Med. 1985;56:505–18.

    PubMed  CAS  Google Scholar 

  85. Socha P, Ryzko J, Janczyk W, Dzik E, Iwanczak B, Krzesiek E. Hepatic vein thrombosis as a complication of ulcerative colitis in a 12-year-old patient. Dig Dis Sci. 2007;52:1293–8.

    Article  PubMed  Google Scholar 

  86. Chesner IM, Muller S, Newman J. Ulcerative colitis complicated by Budd-Chiari syndrome. Gut. 1986;27:1096–100.

    Article  PubMed  CAS  Google Scholar 

  87. CoS M. Fitness, health CoS. Active healthy living: prevention of childhood obesity through increased physical activity. Pediatrics. 2006;117:1834–42.

    Article  Google Scholar 

  88. Kugathasan S, Nebel J, Skelton J, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr. 2007;151:523–7.

    Article  PubMed  Google Scholar 

  89. Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol. 1989;13 Suppl 1:43–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Gastroenterology, Hepatology, and Nutrition, University of Toronto, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada, M5G 1X8

    Pamela L. Valentino MDCM, FRCP(C) & Binita M. Kamath MBBChir, MRCP, MTR

Authors
  1. Pamela L. Valentino MDCM, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Binita M. Kamath MBBChir, MRCP, MTR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Binita M. Kamath MBBChir, MRCP, MTR .

Editor information

Editors and Affiliations

  1. Perelman School of Medicine, The Children’s Hospital of Philadelphia, University of Pennsylvania, 34th St. & Civic Ctr. Blvd., Philadelphia, 19104, Pennsylvania, USA

    Petar Mamula

  2. School of Medicine--Greenville, Pediatric Gastroenterology & Nutrition, University of South Carolina, 200 Patewood Drive, Suite A-140, Greenville, 29615, South Carolina, USA

    Jonathan E. Markowitz

  3. Perelman School of Medicine, The Children's Hospital of Philadelphia, University of Pennsylvania, 34th St. & Civic Ctr. Blvd., Philadelphia, 19104, Pennsylvania, USA

    Robert N. Baldassano

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Valentino, P.L., Kamath, B.M. (2013). Liver Disease in Pediatric Inflammatory Bowel Disease. In: Mamula, P., Markowitz, J., Baldassano, R. (eds) Pediatric Inflammatory Bowel Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5061-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5061-0_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5060-3

  • Online ISBN: 978-1-4614-5061-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation